Walleye Capital
DNTH icon

Walleye Capital’s Dianthus Therapeutics DNTH Stock Holding History

Walleye Capital’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.9M Sell
153,585
-52,230
-25% -$3.02M 0.05% 313
2025
Q4 		$8.48M Buy
205,815
+64,686
+46% +$2.51M 0.03% 761
2025
Q3 		$5.55M Buy
141,129
+114,996
+440% +$2.94M 0.02% 867
2025
Q2 		$487K Sell
26,133
-80,798
-76% -$1.52M ﹤0.01% 2656
2025
Q1 		$1.94M Buy
106,931
+24,041
+29% +$530K 0.01% 1439
2024
Q4 		$1.81M Buy
82,890
+52,890
+176% +$1.36M ﹤0.01% 1870
2024
Q3 		$821K Buy
+30,000
New +$836K ﹤0.01% 2844
2024
Q2 		– Sell
-190,266
Closed -$5.71M – 5675
2024
Q1 		$5.71M Buy
+190,266
New +$4.14M 0.01% 1202
2022
Q2 		– Sell
-2,584
Closed -$120K – 2454
2022
Q1 		$120K Buy
2,584
+835
+48% +$45.6K ﹤0.01% 1692
2021
Q4 		$124K Buy
+1,749
New +$176K ﹤0.01% 1615

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Capital's DNTH Position: Q1 2026 in Review

Walleye Capital reduced its Dianthus Therapeutics (DNTH) stake by 25% in Q1 2026, selling an estimated $3.02M and leaving 153,585 shares worth $12.9M. The position accounts for 0.05% of the portfolio, ranked #313.

Walleye Capital first reported a position in DNTH in Q4 2021 and has held it in 10 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Walleye Capital held 153,585 shares of Dianthus Therapeutics worth $12.9M as of Q1 2026.
  • Walleye Capital sold 52,230 Dianthus Therapeutics shares in Q1 2026, an estimated $3.02M.
  • Dianthus Therapeutics made up 0.05% of Walleye Capital's portfolio in Q1 2026, its #313 holding.
  • Walleye Capital first reported a position in Dianthus Therapeutics in Q4 2021 and has held it in 10 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.